GSK is the fifth company to leave BIO in roughly a year, a group that includes Pfizer and UCB. The departures coincided with ...

Have a nice week! It’s hard to know exactly what change in Washington will mean for the health care industry starting next ...

A total of 739 deals were completed so far this year representing a decrease of just under 21 per cent compared to last year.

Nature’s Bounty Co., NOW Foods, Pfizer Inc., Bayer AG, GlaxoSmithKline (GSK), GNC Holdings ... Food and Beverage, Consumer ...

In October 2023, Sanofi announced plans to separate its consumer health unit in 2024. Sanofi’s consumer health division, with ...

Pfizer (NYSE: PFE) is in that group, in my opinion. The big drugmaker's forward dividend yield currently stands at just under ...

The global glucosamine supplement market is projected to grow from USD 583.6 million in 2023 to USD 932.7 million by 2033, expanding at a CAGR of 4.8%, according to Future Market Insights. The rising ...

Haleon backed its full-year guidance despite lower third-quarter revenue and earnings, although organic revenue growth of 6.1% topped its own forecasts.

US-based investment firm takes controlling stake in Opella, while France's government moves to ensure the company remains in ...

GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.1 at the end of 2023 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...

Secondary Myelofibrosis Therapeutics MarketThe global secondary myelofibrosis therapeutics market, valued at USD 1.4 million in 2022, is set to experience notable growth over the coming decade, ...

Global Stuttering Therapeutics MarketThe global stuttering therapeutics market, valued at USD 43 million in 2023, is on track ...